ZOLL X Series defibrillator gets FDA's OK
The key piece of this device everyone wants their hands on is the communications suite
ZOLL Medical recently won 510(k) clearance from the FDA for its ZOLL X monitor/defibrillator, a smaller, more powerful device aimed at the EMS market.
"We believe the X Series is a game changer for ZOLL in the EMS market. We have the size and weight advantages that ZOLL is known for without compromising features or functionality," President Jonathan Rennert said in prepared remarks.
"The X Series has every advanced monitoring and communication capability required by EMS providers and, ultimately, critical care transport operations."
The X Series is described as about half the size and half the weight of competitive full-featured monitor/defibrillators, yet is much more powerful and built to the most extensive standards for ruggedness.
Weighing less than 12 pounds (6 kilograms), the X Series is compact without compromise in capability, performance or display size. This monitor/defibrillator combines ZOLL defibrillation, pacing and CPR assistance with advanced monitoring and built in communications.
There has been much in the news about ZOLL Medical lately, with Japan's Asahi Kasei announcing their acquisition of the company last month.
World-class ZOLL engineering combined with Japanese high-tech innovation could be a real powerhouse. We may be about to see ZOLL really take off.
The key piece of this device everyone wants their hands on is the communications suite. ZOLL has been quietly working for years on a final EMS telemedicine solution.
The ZOLL X can bring all the field medical data to base command. More than just an ECG device, the new ZOLL X series promises to change the face of health care communictions in EMS.
Join the discussion
The comments below are member-generated and do not necessarily reflect the opinions of EMS1.com or its staff. If you cannot see comments, try disabling privacy and ad blocking plugins in your browser. All comments must comply with our Member Commenting Policy.